Hospital

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial.

Nemolizumab shows promising long-term efficacy in reducing itch and skin lesions for atopic dermatitis, enhancing quality of life for patients.

Moderna's mRNA-1345 vaccine gains FDA approval, enhancing protection against RSV for high-risk adults aged 18 to 59 years, following earlier approvals for older populations.

Ribociclib plus endocrine therapy shows improved survival in HR+, HER2- breast cancer, but its cost-effectiveness raises concerns in the US market.

In 3 phase 3 clinical trials, enlicitide decanoate demonstrated clinically significant reductions in low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia and familial hypercholesterolemia.

The investigational blood test achieved 99% sensitivity and specificity.

The data from the 5-year analysis of arm C validate and support the efficacy and safety of zanubrutinib for treatment-naive patients with CLL/SLL harboring del(17p).

Pharmacists are redefining health care by bridging clinical and economic evidence, making a real difference in patient outcomes through health economics and outcomes research (HEOR).

Pembrolizumab gains FDA approval as a groundbreaking neoadjuvant treatment for resectable locally advanced head and neck squamous cell carcinoma, enhancing patient outcomes.

Mitomycin intravesical solution is the first FDA-approved treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer.

Significant challenges persist, particularly in low- and middle-income countries.

Pharmacists play a critical role in managing complex pericarditis cases.

The expansion marks glecaprevir/pibrentasvir as the first and only indicated direct-acting antiviral approved for acute hepatitis C virus (HCV) infection.

A multidisciplinary, technology-enhanced approach supported by executive leadership is essential for effective drug diversion surveillance and regulatory compliance in health systems.

Meloxicam injection gains FDA approval for effective management of moderate-to-severe pain, offering a nonopioid alternative in pain control strategies.

Nivolumab plus relatlimab does not significantly improve recurrence-free survival in patients with stage 3, 4 melanoma.

As policy developments unfold rapidly at both the state and federal levels, Tom Kraus highlights the expanding scope of pharmacist practice through a wave of state-level legislation as a key opportunity.

Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option.

A new study reveals the combination therapy enhances safety and efficacy for high-risk BRAF-mutated stage II melanoma.

Cilta-cel shows promise as a CAR T-cell therapy, offering long-term remission for patients with relapsed/refractory multiple myeloma without maintenance treatment.

The findings highlight the need for improved prescribing practices and patient outcomes.

Standardized online modules ensure consistent, high-quality care in collaborative practice agreements.

Pharmacists lead the charge in implementing advanced therapeutics, navigating complex challenges and shaping the future of health care innovation.

Ambulatory pharmacists innovate care delivery, enhancing patient access and outcomes through home visits and harm reduction clinics for complex health needs.

Integrating specialty pharmacists into neurology teams enhances patient care, medication management, and clinical outcomes for chronic conditions.

Innovative pain management strategies emerge as experts advocate for personalized, multifaceted approaches to chronic pain, likening treatment to a tailored cupcake.